FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers drugs, and concerns an anticancer composition containing: a) a therapeutically effective amount of 13-deoxyantracycline of formula specified below and b) a therapeutically effective amount of taxane. Also, there are disclosed pharmaceutical formulation and cancer therapy involving the introduction of the therapeutically effective amount of 13-deoxyantracycline and the therapeutically effective amount of taxane.
EFFECT: compositions under the invention synergetically inhibit cancer cell growth and provide considerable side effect reduction 
where each of R1, R2, R3, R4, R5 and R6 have the values specified in formula.
9 cl, 4 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 3'-DEAMINO-3'-(2"-PYRROLINE-1"-YL)-5-IMINO-13-DEOXYANTRACYCLINS AND PRODUCTION METHODS | 2018 |
|
RU2803586C2 |
| TAXANES COVALENTLY BONDED WITH HYALURONIC ACID OR HYALURONIC ACID DERIVATIVES | 2003 |
|
RU2384593C2 |
| METHOD AND COMPOSITION FOR PERORAL INTAKE OF TAXANES BY A PATIENT | 1998 |
|
RU2205005C2 |
| HIGHLY EFFECTIVE METHOD FOR PREPARING DOSAGE FORM OF TARGETED ACTION FOR THERAPY OF MALIGNANT GROWTHS | 2019 |
|
RU2727924C1 |
| ANTI-ANGIOGENESIS THERAPY USED FOR TREATING BREAST CANCER | 2009 |
|
RU2531948C2 |
| COMBINATION TREATMENT | 2014 |
|
RU2666999C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| TREATING THREE RECEPTOR NEGATIVE BREAST CANCER | 2007 |
|
RU2448697C2 |
| DERIVATIVES OF 5-IMINO-13-DEOXYANTHRACYCLINE AND METHOD FOR THEIR PREPARING (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD FOR TREATMENT OF CANCER, AUTOIMMUNE DISEASES OR IMMUNODEFICIENT DISORDERS | 1999 |
|
RU2239640C2 |
